SeqLL

17 articles about SeqLL

• SeqLL Defers Proposed Cash and Stock Distributions to Stockholders in Connection With Proposed Acquisition

  10/30/2023

  SeqLL Inc., announced the decision of its Board of Directors to cancel the special cash dividend and stock dividend that it intended to make to its common stockholders in connection with, and subject to, the consummation of its planned acquisition of Lyneer Investments LLC and the disposition of its current business operations.

• SeqLL to Conduct 1-for-40 Reverse Stock Split

  8/30/2023

  SeqLL Inc., a technology company providing life sciences instrumentation and research services, announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-40.

• SeqLL Provides First Quarter 2023 Financial Results

  5/9/2023

  SeqLL Inc. announced its operating and financial results for the first quarter ended March 31, 2023.

• SeqLL Inc. Announces Closing of $1.8 Million Registered Direct Offering

  2/15/2023

  SeqLL Inc., a technology company providing life sciences instrumentation and research services, announced the closing of its previously announced registered direct offering of 2,000,000 shares of common stock at a purchase price of $0.90 per share of common stock.

• SeqLL Inc. Announces Pricing of $1.8 Million Registered Direct Offering

  2/13/2023

  SeqLL Inc., a technology company providing life sciences instrumentation and research services, announced that it has entered into a securities purchase agreement with institutional investors to purchase 2,000,000 of its shares of common stock at a purchase price of $0.90 per share of common stock in a registered direct offering.

• SeqLL Announces CRADA with the FBI

  2/7/2023

  SeqLL Inc., a technology company providing life sciences instrumentation and research services, announced the establishment of a two-year Cooperative Research and Development Agreement with the U.S. Department of Justice’s Federal Bureau of Investigation.

• Brian Paras joins SeqLL as Chief Business Officer

  12/13/2022

  SeqLL Inc., a technology company providing life sciences instrumentation and research services, announced that Brian Paras has joined the company as Chief Business Officer.

• UPDATE -- SeqLL Announces Peer-Reviewed Publication of Novel Single-Molecule Liquid Biopsy Method in Nature Biotechnology

  9/13/2022

  SeqLL Inc. announced a new study demonstrating early cancer detection using SeqLL’s single-molecule technology was published in the peer-reviewed journal Nature Biotechnology.

• SeqLL to Present at the H.C. Wainwright 24th Annual Global Conference

  9/6/2022

  SeqLL Inc. announced that Daniel Jones, CEO of SeqLL will present a corporate overview and be available for virtual 1x1 meetings at the upcoming H.C. Wainwright 24th Annual Global Conference taking place from September 12-14, 2022.

• SeqLL’s Single-Molecule Nucleosome Imaging Method Published in Peer Reviewed Cell Reports Journal

  6/13/2022

  SeqLL Inc. announced a new study utilizing its single-molecule epigenetic profiling technology was published in the peer-reviewed journal Cell Reports.

• SeqLL Provides First Quarter 2022 Financial Results and a Corporate Update

  5/13/2022

  SeqLL Inc. announced its operating and financial results for the first quarter ended March 31, 2021, and provided a corporate update.

• SeqLL Announces Fourth Quarter and Year End 2021 Financial Results and Provides a Corporate Update

  3/30/2022

  SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ: SQL; SQLLW), a technology company providing life sciences instrumentation and research services in collaborative partnerships aimed at the development of novel scientific assets and intellectual property, today announced its operating and financial results for the fourth quarter and year ended December 31, 2021.

• SeqLL to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest

  3/24/2022

  SeqLL Inc. announced that Daniel Jones, CEO of SeqLL will participate at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, taking place on March 28-30, 2022.

• SeqLL Announces Formation of Scientific Advisory Board

  3/21/2022

  SeqLL Inc., a technology company providing life sciences instrumentation and research services for collaborative partnerships, announced the formation of a Scientific Advisory Board comprised of distinguished and world-renowned leaders of the scientific community.

• SeqLL Announces Publication of a New Blood-Based RNA Sequencing Method to Detect Coronary Artery DiseaseGW-Led Research uses SeqLL’s tSMS® platform to identify novel signature for detection of coronary artery disease

  9/27/2021

  SeqLL Inc. announced the peer-reviewed publication of a new blood-based RNA Sequencing method to detect Coronary Artery Disease powered by SeqLL’s tSMS platform in the September issue of BMC Medical Genomics.

• SeqLL Installs true Single Molecule Sequencing (tSMS) Instrument to Support Oncology Research by Dr. David Ting, MD at the Harvard-MGH Cancer Center

  11/3/2017

  Dr. Ting is Assistant Professor of Medicine at Harvard Medical School and a medical oncologist with a focus on gastrointestinal malignancies.

• SeqLL Awarded SBIR To Advance The Development Of Direct RNA Sequencing (DRS) Technology

  7/12/2017